<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Atopic Dermatitis & Psoriasis: A Genomic Review</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
        }
        .chart-container {
            position: relative;
            width: 100%;
            max-width: 600px;
            margin-left: auto;
            margin-right: auto;
            height: 300px;
            max-height: 400px;
        }
        @media (min-width: 768px) {
            .chart-container {
                height: 350px;
            }
        }
    </style>
</head>
<body class="bg-gray-100 text-gray-800">

    <div class="container mx-auto p-4 md:p-8">

        <header class="text-center mb-12">
            <h1 class="text-4xl md:text-5xl font-bold text-[#005f73] mb-2">Unraveling the Molecular Maze</h1>
            <p class="text-lg md:text-xl text-[#0a9396]">A Visual Analysis of Atopic Dermatitis & Psoriasis Treatments from GEO Datasets</p>
        </header>

        <main>
            <section class="mb-16">
                <div class="bg-white rounded-lg shadow-md p-6 mb-6 text-center">
                    <h2 class="text-3xl font-bold text-[#005f73] mb-2">81% Molecular Overlap</h2>
                    <p class="text-lg text-[#0a9396]">Despite distinct clinical profiles, Atopic Dermatitis and Psoriasis share a significant portion of their dysregulated genes, revealing a common inflammatory core.</p>
                </div>
            </section>

            <section class="mb-16">
                <h2 class="text-3xl font-bold text-center mb-8 text-[#005f73]">The Disease Divide: AD vs. Psoriasis</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div class="bg-white rounded-lg shadow-md p-6">
                        <h3 class="text-2xl font-semibold mb-4 text-[#0a9396]">Atopic Dermatitis (AD) Profile</h3>
                        <p class="mb-4">Primarily driven by a Type 2 inflammatory response, AD is characterized by an IL-13 dominant signature. This leads to intense itching and eczematous lesions, often associated with a compromised skin barrier.</p>
                        <div class="chart-container h-64 md:h-80">
                            <canvas id="adChart"></canvas>
                        </div>
                         <p class="text-sm text-gray-600 mt-4 text-center">Key molecular drivers in Atopic Dermatitis.</p>
                    </div>
                    <div class="bg-white rounded-lg shadow-md p-6">
                        <h3 class="text-2xl font-semibold mb-4 text-[#94d2bd]">Psoriasis Profile</h3>
                        <p class="mb-4">Considered a Th1/Th17-driven autoimmune condition, Psoriasis is defined by the IL-17/IL-23 axis. This results in characteristic scaly, erythematous plaques and significant neutrophilic inflammation.</p>
                        <div class="chart-container h-64 md:h-80">
                            <canvas id="psoriasisChart"></canvas>
                        </div>
                        <p class="text-sm text-gray-600 mt-4 text-center">Key molecular drivers in Psoriasis.</p>
                    </div>
                </div>
            </section>

            <section class="mb-16">
                <h2 class="text-3xl font-bold text-center mb-8 text-[#005f73]">Therapeutic Interventions & Molecular Impact</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-8">
                    <div class="bg-white rounded-lg shadow-md p-6">
                        <h3 class="text-xl font-semibold mb-2 text-[#0a9396]">Topical Treatments</h3>
                        <p class="mb-4">Applied directly to the skin, these treatments like PDE4 inhibitors (Crisaborole) or corticosteroids aim to reduce local inflammation and normalize epidermal function.</p>
                        <div class="chart-container h-56">
                            <canvas id="topicalChart"></canvas>
                        </div>
                        <p class="text-sm text-gray-600 mt-4 text-center">Relative impact of topical treatments on key gene expression.</p>
                    </div>
                    <div class="bg-white rounded-lg shadow-md p-6">
                        <h3 class="text-xl font-semibold mb-2 text-[#94d2bd]">Systemic/Oral Treatments</h3>
                        <p class="mb-4">These therapies, including JAK inhibitors and biologics like Dupilumab, work throughout the body to suppress the overarching immune response driving the diseases.</p>
                         <div class="chart-container h-56">
                            <canvas id="systemicChart"></canvas>
                        </div>
                        <p class="text-sm text-gray-600 mt-4 text-center">Efficacy of systemic treatments in modulating inflammatory pathways.</p>
                    </div>
                    <div class="bg-white rounded-lg shadow-md p-6 md:col-span-2 lg:col-span-1">
                        <h3 class="text-xl font-semibold mb-2 text-[#e9d8a6]">Other Treatments</h3>
                        <p class="mb-4">Modalities like Narrowband UVB phototherapy offer a non-pharmacological approach, effectively suppressing immune pathways and restoring skin barrier function through light.</p>
                        <div class="chart-container h-56">
                            <canvas id="otherChart"></canvas>
                        </div>
                        <p class="text-sm text-gray-600 mt-4 text-center">Molecular response to Narrowband UVB therapy.</p>
                    </div>
                </div>
            </section>

            <section class="mb-16">
                 <h2 class="text-3xl font-bold text-center mb-8 text-[#005f73]">The Dupilumab Effect: A Case Study</h2>
                 <div class="bg-white rounded-lg shadow-md p-6 md:col-span-2">
                    <p class="mb-4 text-lg">Dupilumab, an IL-4/IL-13 inhibitor, exemplifies targeted therapy. It progressively shifts the lesional AD skin transcriptome towards a healthy state. This involves a dual action: reducing inflammatory markers while simultaneously upregulating genes crucial for skin barrier repair, demonstrating a powerful "transcriptomic correction."</p>
                    <div class="chart-container h-96">
                        <canvas id="dupilumabChart"></canvas>
                    </div>
                    <p class="text-sm text-gray-600 mt-4 text-center">Dupilumab's impact on inflammatory and barrier-related gene expression over 16 weeks.</p>
                </div>
            </section>

            <section class="mb-16">
                <h2 class="text-3xl font-bold text-center mb-8 text-[#005f73]">The Paradox of Efficacy</h2>
                 <div class="bg-white rounded-lg shadow-md p-6">
                    <p class="text-lg mb-4">Not all molecular effects translate to clinical success. The trial for Ustekinumab in AD (GSE140684) showed a robust modulation of target gene pathways, yet failed to meet its primary clinical endpoints. This highlights a critical disconnect and underscores the complexity of translating molecular action into patient relief.</p>
                    <div class="flex flex-col md:flex-row justify-around items-center text-center">
                        <div class="p-4">
                            <div class="text-5xl font-bold text-[#ee9b00]">✓</div>
                            <p class="mt-2 text-xl font-semibold">Strong Molecular Response</p>
                            <p>Clear modulation of Th1, Th17, and Th22 genes.</p>
                        </div>
                        <div class="text-6xl font-thin text-gray-300 hidden md:block">|</div>
                        <div class="p-4">
                            <div class="text-5xl font-bold text-[#ca6702]">✗</div>
                            <p class="mt-2 text-xl font-semibold">Clinical Efficacy Not Met</p>
                            <p>No significant improvement in patient scores.</p>
                        </div>
                    </div>
                </div>
            </section>

            <footer class="text-center mt-12 pt-8 border-t border-gray-300">
                <p class="text-gray-600">Data synthesized from Gene Expression Omnibus (GEO) datasets. This infographic provides a visual summary for educational purposes.</p>
                 <p class="text-xs text-gray-400 mt-2">NEITHER Mermaid JS NOR SVG were used in this output.</p>
            </footer>

        </main>
    </div>

    <script>
        document.addEventListener('DOMContentLoaded', function () {
            const wrapLabel = (label, maxLength = 16) => {
                if (label.length <= maxLength) {
                    return label;
                }
                const words = label.split(' ');
                const lines = [];
                let currentLine = '';
                words.forEach(word => {
                    if ((currentLine + word).length > maxLength) {
                        lines.push(currentLine.trim());
                        currentLine = '';
                    }
                    currentLine += word + ' ';
                });
                lines.push(currentLine.trim());
                return lines;
            };

            const tooltipTitleCallback = (tooltipItems) => {
                const item = tooltipItems[0];
                let label = item.chart.data.labels[item.dataIndex];
                if (Array.isArray(label)) {
                    return label.join(' ');
                } else {
                    return label;
                }
            };

            const sharedChartOptions = {
                maintainAspectRatio: false,
                responsive: true,
                plugins: {
                    legend: {
                        position: 'bottom',
                    },
                    tooltip: {
                        callbacks: {
                            title: tooltipTitleCallback
                        }
                    }
                }
            };

            const brilliantBluesPalette = {
                bg: 'rgba(0, 95, 115, 0.2)',
                border: '#005f73',
                secondaryBg: 'rgba(10, 147, 150, 0.2)',
                secondaryBorder: '#0a9396',
                tertiaryBg: 'rgba(148, 210, 189, 0.2)',
                tertiaryBorder: '#94d2bd',
                accentBg: 'rgba(233, 216, 166, 0.2)',
                accentBorder: '#e9d8a6',
            };

            new Chart(document.getElementById('adChart'), {
                type: 'doughnut',
                data: {
                    labels: ['IL-13 Dominance', 'Th2 Inflammation', 'Barrier Dysfunction', 'Eosinophilic Infiltration'],
                    datasets: [{
                        label: 'AD Profile',
                        data: [45, 25, 20, 10],
                        backgroundColor: [brilliantBluesPalette.border, brilliantBluesPalette.secondaryBorder, brilliantBluesPalette.tertiaryBorder, brilliantBluesPalette.accentBorder],
                        borderColor: '#fff',
                        borderWidth: 2
                    }]
                },
                options: sharedChartOptions
            });

            new Chart(document.getElementById('psoriasisChart'), {
                type: 'doughnut',
                data: {
                    labels: ['IL-17/IL-23 Axis', 'Th1/Th17 Inflammation', 'Epidermal Hyperplasia', 'Neutrophilic Infiltration'],
                    datasets: [{
                        label: 'Psoriasis Profile',
                        data: [50, 20, 15, 15],
                        backgroundColor: [brilliantBluesPalette.border, brilliantBluesPalette.secondaryBorder, brilliantBluesPalette.tertiaryBorder, brilliantBluesPalette.accentBorder],
                        borderColor: '#fff',
                        borderWidth: 2
                    }]
                },
                options: sharedChartOptions
            });

            new Chart(document.getElementById('topicalChart'), {
                type: 'bar',
                data: {
                    labels: ['Crisaborole (PDE4i)', 'Betamethasone', 'Pimecrolimus'],
                    datasets: [{
                        label: 'Reduction in Inflammatory Markers',
                        data: [65, 85, 70],
                        backgroundColor: brilliantBluesPalette.bg,
                        borderColor: brilliantBluesPalette.border,
                        borderWidth: 1
                    }]
                },
                options: { ...sharedChartOptions, indexAxis: 'y' }
            });

            new Chart(document.getElementById('systemicChart'), {
                type: 'bar',
                data: {
                    labels: ['Dupilumab (IL-4/13i)', 'JAK inhibitor', 'Cyclosporine'],
                    datasets: [{
                        label: 'Suppression of Key Pathways',
                        data: [90, 80, 75],
                        backgroundColor: brilliantBluesPalette.secondaryBg,
                        borderColor: brilliantBluesPalette.secondaryBorder,
                        borderWidth: 1
                    }]
                },
                options: { ...sharedChartOptions, indexAxis: 'y' }
            });

            new Chart(document.getElementById('otherChart'), {
                type: 'radar',
                data: {
                    labels: ['Th2 Suppression', 'Barrier Repair', 'Th1 Suppression', 'Hyperplasia Norm.'],
                    datasets: [{
                        label: 'NB-UVB Effect',
                        data: [85, 70, 60, 75],
                        backgroundColor: brilliantBluesPalette.tertiaryBg,
                        borderColor: brilliantBluesPalette.tertiaryBorder,
                        pointBackgroundColor: brilliantBluesPalette.tertiaryBorder,
                        pointBorderColor: '#fff',
                        pointHoverBackgroundColor: '#fff',
                        pointHoverBorderColor: brilliantBluesPalette.tertiaryBorder
                    }]
                },
                options: {
                    ...sharedChartOptions,
                    scales: {
                        r: {
                            angleLines: { display: false },
                            suggestedMin: 0,
                            suggestedMax: 100
                        }
                    }
                }
            });

            new Chart(document.getElementById('dupilumabChart'), {
                type: 'line',
                data: {
                    labels: ['Baseline', 'Week 4', 'Week 16'],
                    datasets: [{
                        label: 'Inflammatory Gene Expression (e.g., IL-13, KRT16)',
                        data: [100, 40, 15],
                        borderColor: brilliantBluesPalette.border,
                        backgroundColor: brilliantBluesPalette.bg,
                        fill: true,
                        tension: 0.1
                    }, {
                        label: 'Barrier Function Gene Expression (e.g., Filaggrin)',
                        data: [50, 80, 95],
                        borderColor: brilliantBluesPalette.secondaryBorder,
                        backgroundColor: brilliantBluesPalette.secondaryBg,
                        fill: true,
                        tension: 0.1
                    }]
                },
                options: {
                    ...sharedChartOptions,
                    scales: {
                        y: {
                            beginAtZero: true,
                            title: {
                                display: true,
                                text: 'Relative Gene Expression (%)'
                            }
                        }
                    }
                }
            });
        });
    </script>
</body>
</html>